Abstract
Indirect and circumstantial clinical evidence suggests that often occurs tumor progression. In stage breast cancer, for example, a significant percentage of patients exhibit circulating tumor cells (CTC's) and disseminated bone marrow tumor cells (DTC's) [[1, [2]. More direct experimental evidence for early metastasis has been observed studies of transgenic mice expressing a cancer-causing oncogene where the primary cancer on exists an in stage yet bone marrow metastases are discovered [3]. If indeed occurs early, then the rate-limiting steps which give rise to must also occur early. Some rate-limiting steps include both angiogenesis as well as lymphangiogenesis. However there have been alternate short-circuiting mechanisms proposed for these phenomenon including vasculogenic mimicry [4]. Another key rate-limiting step the metastatic process is tumoral embolic formation within lymphovascular channels. The canonical view of the origin of tumor lymphovascular emboli is that they directly originate from lymphovascular invasion. We found evidence, however that tumoral lymphovascular emboli can result from the short-circuiting step of encircling lymphovasculogenesis [5]. Experimentally, we used a xenograft of human inflammatory breast cancer (MARY-X), a model that exhibited florid tumor emboli, to generate tumoral spheroids vitro. In observational studies, we chose human breast carcinoma cases where there appeared to be a possible transition of situ carcinoma to lymphovascular emboli without intervening stromal invasion. These cases were studied by morphometry as well as IHC with tumor proliferation (Ki-67) and adhesion (E-cadherin) markers, myoepithelial (p63), as well as endothelial (podoplanin [D2-40], CD31, VEGFR-3, Prox-1) markers. Unlabelled spheroids coinjected with either GFP or RFP-human myoepithelial cells or murine embryonal fibroblasts (MEFs) gave rise to tumors which exhibited GFP/RFP immunoreactivity within the cells lining the emboli-containing lymphovascular channels. In vitro studies demonstrated that the tumoral spheroids induced endothelial differentiation of cocultured myoepithelial cells and MEFs, measured by real time PCR and immunofluorescence. In humans, the DCIS clusters exhibited similar proliferation, E-cadherin immunoreactivity and size as the tumor emboli (p =.5), suggesting the possibility that the latter originated from the former. The DCIS clusters exhibited a loss (50%-100%) of p63 myoepithelial immunoreactivity but not E-cadherin epithelial immunoreactivity. The tumor emboli were mainly present within lymphatic channels whose dual p63/CD31, p63/D2-40 and p63/VEGFR-3 and overall weak patterns of D2-40/CD31/VEGFR-3 immunoreactivities suggested that they represented immature and newly created vasculature derived from originally myoepithelial-lined ducts. Collectively both experimental as well as observational studies suggested the possibility that these breast cancer emboli resulted from encircling lymphovasculogenesis rather than conventional lymphovascular invasion. Encircling lymphovasculo-genesis as the mechanism of lymphovascular invasion represents a paradigm shift our thinking about this phenomenon. The lymphovascular embolus represents the phenomenon of the the where the arduous and complex task of constructing a ship within a bottle is replaced with the relatively effortless and simple job of building the bottle around the ship [5].
Highlights
Indirect and circumstantial clinical evidence suggests that metastasis often occurs early in tumor progression
There have been alternate short-circuiting mechanisms proposed for these phenomenon including vasculogenic mimicry [4]
The canonical view of the origin of tumor lymphovascular emboli is that they directly originate from lymphovascular invasion
Summary
Indirect and circumstantial clinical evidence suggests that metastasis often occurs early in tumor progression. In early stage breast cancer, for example, a significant percentage of patients exhibit circulating tumor cells (CTC’s) and disseminated bone marrow tumor cells (DTC’s) [1,2].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.